Wolff-Parkinson-White Syndrome (WPWS)

Wolff-Parkinson-White syndrome (WPWS) is associated with palpitations, dyspnea, dizziness, or syncope. In extraordinary cases, it can result in a person's sudden cardiac arrest and sudden death. Although the age of manifestation is from 11 to 50 years, complications may occur at any age. Protheragen is a primary research service provider focusing comprehensively on the understanding and therapy research of rare cardiovascular diseases like WPWS. We focus on providing an integrated solution throughout the drug discovery and development process, ensuring our clients receive the best support from diagnosis through to therapy innovations.

Introduction to Wolff-Parkinson-White Syndrome (WPWS)

Wolff-Parkinson-White syndrome (WPWS) also known as pre-excitation syndrome, is an inherited abnormality of the heart termed a genetic disorder that causes arrhythmia as a result of an abnormal electrical pathway in the heart, an accessory pathway that enables electrical signals to circumvent the atrioventricular node and transmit from the atria to the ventricles at a rate exceeding the normal speed. This pathway may also be capable of transmitting electrical impulses in the opposite direction, leading to arrhythmias.

Fig.1 Atrioventricular conduction in WPWS. (Vatasescu, R. G., et al., 2024)

Pathogenesis of Wolff-Parkinson-White Syndrome (WPWS)

Familial Wolff-Parkinson-White Syndrome (WPWS) is a disease with autosomal dominant inheritance and accounts for a small subset of WPWS which shows ventricular pre-excitation due to the development of an accessory atrioventricular pathway.

A range of familial WPWS causes have been reported due to mutations in the PRKAG2 gene which codes for the gamma two subunit of 5'AMP-activated protein kinase (AMPK). One of the most important metabolic regulators of carbohydrates and lipids in a variety of tissues such as cardiac and skeletal muscle is the AMPK. Several individuals and animal models that bear the mutation in the PRKAG2 gene show aberrant atrioventricular conduction with cardiac glycogen overload.

Therapeutics Development for Wolff-Parkinson-White Syndrome (WPWS)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a therapy plan recommendation. For guidance on therapy options, please visit a regular hospital.

Our Services

At the core of all our undertakings, a skilled cadre of scientists and professionals from diverse industries is dedicated to the innovation of our projects. We provide a complete range of preclinical evaluation services spanning the creation of diagnostics, therapeutics, and disease models. Such integration enables the efficient bridging of the discovery and application practice.

Therapeutic Development Services

Diverse Platforms

• Small Molecule Drug Development
• Gene Therapy Development
• Therapeutic Peptide Development

• Cell Therapy Development
• Therapeutic Antibody Development
• Therapeutic Protein Development

Animal Model Development for WPWS

In the process of developing drugs for WPWS, animal models are especially important, as they provide a controlled setting to investigate foundational mechanisms, evaluate drug effectiveness, and analyze pertinent safety issues. With our company's proven proficiency in specialized molecular techniques, genetic modification, and electrophysiological evaluation, we provide custom animal model development services to solve the difficulties in studying WPWS.

By employing Protheragen's state-of-the-art technology along with bespoke research protocols, precision-tailored solutions are offered for rare cardiovascular diseases. The comprehensive preclinical research services of our company which include in-depth pharmacokinetic studies as well as vigorous evaluations of drug safety, mitigates the risks associated with developing new drugs and therapeutics. Feel free to reach out to us if you want to know more about our services.

Reference

• Vatasescu, Radu Gabriel et al. "Wolf-Parkinson-White Syndrome: Diagnosis, Risk Assessment, and Therapy-An Update." Diagnostics (Basel, Switzerland) 14.3 (2024): 296.